Abstract Objective Commercially available next-generation sequencing (NGS) platforms in China routinely adopt a lung cancer-derived tumor microenvironment (TME) subtyping signature from a European cohort to classify colorectal cancer (CRC), yet its diagnostic performance in Chinese CRC patients remains unvalidated. This study aimed to evaluate the subtyping efficiency of the lung cancer TME signature in a Chinese CRC cohort, screen CRC-specific immune mRNA biomarkers for TME subtyping, and explore the clinical utility of IRF1, CD8A and LAG3 for distinguishing immune-enriched (IE) and immune-de